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Abstract: Cellular receptor-mediated signaling pathways play critical roles during the initial immune
response to Human Cytomegalovirus (HCMV) infection. However, the involvement of type-I
transmembrane glycoprotein CD147/EMMPRIN (extracellular matrix metalloproteinase inducer)
in the antiviral response to HCMV infection is still unknown. Here, we demonstrated the specific
knockdown of CD147 significantly decreased HCMV-induced activation of NF-κB and Interferon-beta
(IFN-β), which contribute to the cellular antiviral responses. Next, we confirmed that HCMV-encoded
miR-US25-1-5p could target the 3′ UTR (Untranslated Region) of CD147 mRNA, and thus facilitate
HCMV lytic propagation at a low multiplicity of infection (MOI). The expression and secretion of
Cyclophilin A (sCyPA), as a ligand for CD147 and a proinflammatory cytokine, were up-regulated
in response to HCMV stimuli. Finally, we confirmed that CD147 mediated HCMV-triggered
antiviral signaling via the sCyPA-CD147-ERK (extracellular regulated protein kinases)/NF-κB axis
signaling pathway. These findings reveal an important HCMV mechanism for evading antiviral
innate immunity through its encoded microRNA by targeting transmembrane glycoprotein CD147,
and a potential cause of HCMV inflammatory disorders due to the secretion of proinflammatory
cytokine CyPA.
Keywords: human cytomegalovirus (HCMV); CD147/EMMPRIN; miR-US25-1-5p; cyclophilin A (CyPA);
ERK/NF-κB signaling pathway; HCMV inflammatory disorders
1. Introduction
Human cytomegalovirus (HCMV) is a widespread human β-herpesvirus with seroprevalence
from 40 to 100%, which is closely related to socioeconomic and geographical conditions [1]. Life-long
latent or persistent HCMV infection can be established in immunocompetent populations after the
primary infection, and productive replication can occur from spontaneous reactivation due to immune
abnormalities. Thus, HCMV is a major viral cause of mental retardation and sensorineural deafness in
newborns, and particularly causes morbidity and mortality in transplant recipients and AIDS patients
with an immunocompromised state [2]. Current studies also tie HCMV to multiple common chronic
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inflammatory diseases, such as cardiovascular disease, autoimmune diseases, inflammatory bowel
diseases (IBDs), and certain cancers [3].
HCMV has a large linear dsDNA genome, with a size of 240-kbp encoding more than 150 open
reading frames (ORFs) and 26 mature miRNAs encoded from 14 pre-miRNAs [4]. The large size of the
viral genome has enabled co-evolution with its host for millions of years, to acquire various and even
redundant strategies for immune evasion, to establish a life-long latent or persistent infection. As a
result, a special balanced immune microenvironment for HCMV, from the interplay between the viral
reactivation and immune response, was established, and intense research on its mechanisms could
potentially contribute to a better understanding of the pathogenesis and biology of this virus.
Since most of the key immune cells, such as NK, T, and B cells, are not productively infected
by HCMV, previous studies mainly focused on how the infection of permissive myeloid lineage
or stromal cells alters the ability of these cells to prime and activate NK (natural killer cell) and T
cells by down-modulating MHC (Major Histocompatibility Complex) and costimulatory molecules,
suppression of activating signals, and provision of inhibitory molecules [5]. In fact, HCMV also uses
diverse tactics to modulate the early immune response. Type I interferons (IFNs) and pro-inflammatory
cytokines are rapidly expressed and secreted by infected cells upon the detection of HCMV binding
and entry [6]. Gene expression profile assays have revealed that large numbers of antiviral genes,
belonging to the interferon stimulated gene (ISG) family and the inflammatory cytokine family,
are strongly induced by early events during HCMV entry [7]. Binding to cellular receptors by HCMV
envelopeglycoproteins can initiate signal transduction pathways, and lead to the activation of NF-κB
and interferon regulatory factor 3 (IRF3), which participates in the subsequent transcription of antiviral
Type I IFNs and pro-inflammatory cytokines [8]. The early immune response is a pivotal time for the
host to defend against HCMV infection. Recombinant IFN-α has been therapeutically used to control
HCMV-induced retinitis in patients with AIDS [9] and congenital viremia with HCMV infection [10].
HCMV proteins have been shown to target early antiviral immune responses. For example, IE86,
encoded by the HCMV immediate-early 2 (IE2) gene, can efficiently suppress HCMV or Sendai virus
(Sev)-induced expression of IFN-β [11]. The HCMV tegument protein UL82 has been reported to inhibit
Stimulator of Interferon Genes (STING)-mediated signaling for evading antiviral innate immunity [12].
Cellular receptor mediated signaling pathways are generally assumed to play an important role
during the earliest immune response to virus infection. In previous studies, Toll-like receptor 2 (TLR2)
has been reported to be critical in the early response to HCMV infection by recognizing the viral
surface glycoproteins gB and gH [13]. Here, CD147/EMMPRIN, a type-I transmembrane glycoprotein
of the immunoglobulin superfamily [14], was found and confirmed to play an important role in
HCMV-triggered early antiviral signaling for the first time. Interestingly, we also found that CD147
expression was down-regulated at the late stages of HCMV infection, and that CD147 was a target
gene for HCMV-encoded miR-US25-1-5p. Simultaneously, the expression and secretion of Cyclophilin
A (sCyPA), which has been reported as a ligand for CD147 [15,16], were up-regulated in response to
HCMV infection. CD147 is a multifunctional transmembrane glycoprotein that is involved in neural
function, pro-inflammation, tumor invasion, and metastasis [17]. Extracellular CypA has been reported
to induce the production of proinflammatory cytokines through direct binding with the ectodomain
of CD147, as seen in our previous work [18]. The specific biological significance and mechanism of
HCMV miR-US25-1-5p by targeting CD147/EMMPRIN, during the early antiviral response to HCMV
infection, were further investigated and discussed in this study.
2. Materials and Methods
2.1. Cells and Viruses
Human foreskin fibroblasts (HFF cells, passages 9 to 14), Human astrocytoma U251 cells
(U251 cells), and Human Embryonic Kidney 293 cells (293 cells) were maintained in Dulbecco’s
modified Eagle medium (DMEM), containing 10% fetal bovine serum, as previously described [19,20].
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Herpes simplex virus 1 (HSV-1) was provided by Fenyong Liu (University of California,
Berkeley, CA, USA). To generate the U251-CD147 overexpressing (U251-CD147) and U251-Control
(U251-C) cell lines, U251 MG cells were transfected with the pcDNA3.1-CD147 plasmid or the
pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA) empty vector control plasmid using LipofectamineTM
2000, as prescribed by the manufacturer (Life Technologies, Waltham, MA, USA). After a 48-h
incubation, transfected cells were selected for resistance in cell culture medium containing 600 µg/mL
G418 (Life Technologies). After two to three weeks of selection, single clones were randomly isolated,
and each was plated separately. The CD147 levels in individual selected clones were determined by
Western blot analysis. The maintenance medium for cell lines was supplemented with 200 µg/mL G418.
The bacterial artificial chromosome (BAC)-derived clinical strain NR-1 with enhanced green fluorescent
protein (eGFP) expression cassette, provided by Dr. Ke Zen (Nanjing University, Nanjing, China),
was used in this study [21]. HCMV mutant (mUS25-1-5p) and the revertant wild type (RvWT)
was generated using a bacterial recombineering method, as previously described [22]. In brief,
approximately 300 bp of the miR-US25-1 flanking region was cloned into the pcDNA3.1(+) vector.
The three nucleotides in the seed region of miR-US25-1-5p were mutated using site-directed polymerase
chain reaction (PCR). Then, the PCR-amplified products containing point mutations of miR-US25-1-5p
were used in the second round of recombination to replace the Tet/Str cassette that inserted in the
region of miR-US25-1-5p at first. The amplified DNA fragments were transformed into E. coli EL350
cells by electroporation (Bio-Rad, Hercules, CA, USA). The bacteria harboring the rescued BACs
were selected in the presence of streptomycin. Mutants were confirmed using BAC DNA sequencing.
Similarly, the BAC of RvWT was generated based on the newly constructed mUS25-1-5p, with two
rounds of recombination. HCMV WT, mUS25-1-5p, and RvWT were propagated in HFF cells, and virus
stocks were stored in DMEM supplemented with 10% fetal bovine serum (FBS) and 1.5% bovine serum
albumin (BSA) at −80 ◦C.
2.2. Reagents and Antibodies
Cyclosporin A (CsA) reagent was obtained from Sigma-Aldrich (St. Louis, MO, USA).
CD147 antibodies (HAb 18, IgG1) were prepared in our laboratory [23]. Dylight 594-conjugated
secondary antibody, used for immunofluorescence, was from Life Technology (San Jose, CA, USA).
We also used anti-HCMV IE1/2 mouse mAb (ab53495, Abcam, Cambridge, UK), rabbit anti-human
CyPA mAb (ab3563, Abcam), phospho-MEK1/2 (Ser217/221) rabbit mAb (#9154, Cell Signaling
Technology (CST), Danvers, MA, USA), Erk1/2 rabbit mAb (#4695, CST), IRF-3 rabbit mAb
(#11904, CST), phospho-IRF-3 (Ser396) rabbit mAb (#29047, CST), NF-κB p65 rabbit mAb (#8242, CST),
phospho-NF-κB p65 (Ser536) rabbit mAb (#3033, CST), and anti-GAPDH mouse mAb (60004-1-Ig,
Proteintech, Rosemont, IL, USA).
2.3. Construction of Plasmids
The following plasmids were used: CD147 pLKO.1 lentiviral shRNA (A6) and
non-target shRNA control plasmid (pLKO.1-NTC) were purchased from Open Biosystems
(GE Healthcare, Little Chalfont, UK). HCMV-encoded miR-US25-1-5p pLKO.1 lentiviral shRNA
(pLKO.1-US25-1-5p) was constructed in this study. pcDNA3.1(+) empty vector was obtained from
Invitrogen (Carlsbad, CA, USA). Full-length CD147-expressing plasmid pcDNA3.1-CD147 was constructed
in our laboratory [24]. Then, the extracellular domain (residues 1–185 of CD147) or intracellular domain
(residues 230–269 of CD147) were deleted to generate pcDNA3.1-CD147-dECD and pcDNA3.1-CD147-dICD,
respectively. The NF-κB-response promoter reporter plasmid (pNF-κB-Luc) and IFN-β promoter reporter
plasmid (pIFN-β-Luc) were obtained from Beyotime (Shanghai, China). Dual luciferase miRNA
target expression vector (pmirGLO) and the Renilla luciferase control reporter plasmid (pRL-TK) were
purchased from Promega (Madison, WI, USA). The pmirGLO-CD1473
′UTR plasmid was made by
inserting the 3′ UTR of the human CD147 gene into the pmirGLO empty vector using the primers
as follows: (forward) 5′-AAGCTAGCGGCAGGTGGCCCGAGGACGCTCCCTG-3′ and (reverse)
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5′-AGTCTAGAGAGGGTGGAGGTGGGGGCGATC-3′. Site-directed mutagenesis was performed
using a QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Stratagene, San Diego, CA, USA)
on the pmirGLO-CD1473
′UTR to generate a pmirGLO-CD1473
′UTRm plasmid with the following
primers: (forward) 5′-AGTCATGGCCGGGTAGACAGCACAGCCTTCT-3′ and (reverse) 5′-AGAAGGCT
GTGCTGTC TACCCGGCCATGACT-3′.
2.4. Indirect Immunofluorescence Assay (IFA)
Cells that were grown on chambered cover slips were infected with HCMV strain NR-1 at a
multiplicity of infection (MOI) of 5. At 6 h posttransfection, cells were fixed with 4% formaldehyde and
blocked with 4% bovine serum albumin (BSA) in PBS and stained with primary mouse IE1/2 antibody
(ab53495, Abcam, Cambridge, UK), and then incubated with the secondary antibody Dylight 594
anti-mouse IgG (Life Technology). Cell nucleus was stained with 4′,6-diamidino-2-phenylindole (DAPI)
(Invitrogen). Images were captured with a Nikon Eclipse TE300 microscope (Diagnostic Instruments,
Inc., Sterling Heights, MI, USA) [20]. The digital images were subsequently merged using FV10 ASW
V4.1 software (Olympus, Tokyo, Japan).
2.5. RNAi-Transduced Stable Cells
The 293 cells were co-transfected with the two packaging plasmids (psPAX2 and pMD2G),
together with a control or RNAi pLKO.1 lentiviral plasmid using LipofectamineTM 2000 (Invitrogen).
The sequence for CD147 shRNA was: 5′-CCCATCATACACTTCCTTCTT-3′ (siCD147); the sequence for
HCMV-miR-US25-1-5p shRNA was: 5′-CCGCTCAGTGGCTCGGACC-3′ (miR-US25-1-5p). After 24 h,
cells were incubated with fresh medium without antibiotics for another 24 h. The medium containing
the recombinant virus was collected and filtered, and then added to HFF or U251 cells in the presence
of 6 mg/mL polybrene. The infected cells were selected by adding puromycin (4–6 mg/mL) to the
culture medium for 14 days before additional experiments. The silencing of expression was verified by
qPCR and Western blot.
2.6. Reporter Gene Assays
Cells (1 × 105) were seeded on 12-well plates and the following day were transfected
using LipofectamineTM 2000 (Invitrogen) and the indicated plasmids. For transfection efficiency
normalization, 0.01 µg Renilla luciferase reporter plasmids (pRL-TK) were added to each transfection.
The total amount of transfeced DNA was maintained at a consistent level by adding empty vector
DNA. Then, 36-h post-transfection, cells were lysed with 200 µL passive lysis buffer (Promega).
Supernatants clarified by centrifugation were used to perform Luciferase assays using the dual
luciferase assay kit (Promega). The values of Firefly luciferase activities were normalized to Renilla
luciferase activities. All of the reporter assays were repeated at least three times in triplicate.
Data shown are average values ± standard deviation (SD) from one representative experiment.
2.7. Real-Time PCR Quantitation of HCMV DNA Level
Viral DNA was extracted from mock or HCMV-infected cells using a DNeasy tissue kit
(Qiagen, Hilden, Germany). Intracellular viral DNAs were quantified using primers and a probe
for amplifying the HCMV UL83 DNA region, as previously described [19]. The reaction was
performed in a 20-µL amplification mixture (2 µL of DNA extract, 10 µL of 2 × Premix Ex TaqTM
(TaKaRa, Dalian, China), 0.4 µL each of primer at 10 µM, 0.8 µL of the fluorogenic probe at 5 µM, 0.4 µL
50 × ROX Reference Dye II) using an ABI 7500 device (Applied Biosystems Inc., Foster City, CA, USA).
PCR cycling conditions were as follows: 95 ◦C for 30 s, 45 cycles at 95 ◦C for 5 s and 60 ◦C for 34 s.
Viral genome copies were normalized to cellular RNase P with thepreviously described primers and
probe [25]. Unknown sample values were determined with a standard curve of known copy numbers
of UL83 (NR-1 BAC) and RNase P. Each set of assays was repeated three times in triplicate, and data
that are shown are average values ± SD from one representative experiment.
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2.8. RNA Extraction and RT-qPCR Assays
Total RNA was isolated with TRIzol reagent (Invitrogen) and cDNA was reverse transcribed
using a PrimeScriptTM RT Reagent Kit (TaKaRa). SYBR-Green real-time PCR (RT-PCR) was performed
with the ABI 7500 device (Applied Biosystems Inc.) using SYBR Premix Ex Taq II (2×) (TaKaRa).
Cellular GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was used to normalize the RNA
inputs. Relative changes in gene expression were analyzed using the 2−∆∆Ct method. All primers were
synthesized by Shanghai GenePharma Co., Ltd., and are listed as following:
CD147: (forward) 5′-TCGCGCTGCTGGGCACC-3′ and (reverse) 5′-TGGCGCTGTCATTCAAG
GA-3′; Cyclophilin A: (forward) 5′-CATGGTCAACCCCACGTGTTCTT-3′ and (reverse) 5′-TAGATGG
ACTTGCCACCAGTGCCAT-3′; IFNB1: (forward) 5′-AGGACAGGATGAACTTTGAC-3′ and (reverse)
5′-TGATAGACATTAGCCAGGAG-3′; IL-6: (forward) 5′-GACAGCCACTCACCTCTTCA-3′ and
(reverse) 5′-AGTGCCTCTTTGCTGCTTTC-3′; ISG15: (forward) 5′-CACAGCCATGGGCTGGGACC
TG-3′ and (reverse) 5′-GCACGCCGATCTTCTGGGTGA-3′; TNF-α: (forward) 5′-ATGAGCACTGAAA
GCATGATCCGG-3′ and (reverse) 5′-CTACAACATGGGCTACAGGCTTGT-3′; GAPDH: (forward)
5′-AGCAATGCCTCCTGCACCACCAAC-3′ and (reverse) 5′-CCGGAGGGGCCATCCACAGTCT-3′.
2.9. Transfection of siRNA into Cells
The chemically synthetic siRNA, targeting the CD147 mRNA CDS region (miR-CD147,
5′-GUUCUUCGUGAGUUCCUCtt-3′) [26], HCMV miR-US25-1-5p (MirBase, MIMAT0001581),
miR-US25-1-3p (MirBase, MIMAT0004755), and 13 other screened HCMV-encoded mature microRNAs
(http://www.mirbase.org/) were synthesized by Ribobio Co., Ltd. (Guangzhou, China), along with
the silencer negative control siRNA (C-siRNA) molecules. The siRNAs were transfected into cells
using LipofectamineTM 2000 (Invitrogen), according to the manufacturer’s instructions.
2.10. Western Blot Analysis
Cells (1 × 108) were washed with cold PBS and lysed with 1 mL NP40 lysis buffer
with 1 mM β-mercaptoethanol and protease inhibitor Cocktail (Roche, Basel, Switzerland) for
30 min on ice. Cell lysates were centrifuged at 12,000 rpm for 30 min, and supernatants were
collected. The protein concentration was determined by BCA assay. Proteins were separated
by 8% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF)
membrane (GE Healthcare). Block in 5% BSA was performed for 1 h in TBS with 0.1% Triton
X-100 (TBST), followed by incubation with primary antibody solution overnight at 4 ◦C. Then,
the membrane was rinsed 3–5 times for 5 min with TBST. After rinsing, the membrane was
incubated with the horse radish peroxidase (HRP)-conjugated secondary antibody solution for 2 h
at room temperature. After another rinsing, the membrane was subsequently reacted with the
chemiluminescent substrate, according to the recommendation of the ECL Western blot detection
reagent kits (Thermo Scientific, Waltham, MA, USA), and were quantitated chemiluminescent signals
using a CCD camera-based imager (Bio-Rad, Hercules, CA, USA). Quantitation was performed in the
linear range of protein detection and analyzed by Image Lab 4.0 software (Bio-Rad). The experiments
were repeated at least three times in triplicate, and a representative result is shown.
2.11. Viral Infection and Growth Curves
Cells (1 × 106) were either mock or HCMV infected at a MOI of 0.05 to 5 in 1.5 mL DMEM with
1% fetal bovine serum. The medium was replaced with 10% fetal bovine serum containing DMEM
after 2 h of incubation. Protein extracts prepared from the infected cells at 3 to 12 days post-infection,
were analyzed by Western blot analysis. To determine viral growth level, cells (1 × 105) were infected
with HCMV at an MOI of 0.05 or 3. Viral stocks were prepared with the total cells and the medium was
harvested 3 to 11 days post-infection by adding an equal volume of 10% (w/v) skim milk, followed by
ultrasonication. The titers of the viral stocks were determined in 1 × 105 HFF cells, with standard virus
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plaque assay and the number of plaques were counted 10 to 14 days after viral infection. The values
obtained were averages ± SD from triplicate experiments [19].
2.12. Statistical Analysis
All of the statistical analyses were performed with GraphPad Prism version 6.00
(GraphPad Software, San Diego, CA, USA). Experiments were repeated at least three times in
triplicate. Data are expressed as mean ± standard deviation. Means between two groups were
compared by using unpaired t-test or one-way analysis of variance (ANOVA) with post hoc Bonferroni
t-test. Differences were considered statistically significant at p < 0.05.
3. Results
3.1. Involvement of CD147 in HCMV Triggered Early Antiviral Response
Many transmembrane receptor proteins have been proposed to mediate signal transduction
pathways that activate the early antiviral immune to HCMV entry [27]. Here, we have investigated the
role of CD147/EMMPRIN in this response. We established two stable knockdowns of CD147, with a
CD147-specific short hairpin RNAs (siCD147) targeting the 3′ UTR of cellular CD147 mRNA, and two
corresponding non-specific RNAi stable cells as controls (siControl) via lentiviral-based transduction
of Human astrocytoma U251 cells (U251 cells) and Human foreskin fibroblasts cells (HFF cells).
CD147 expression was markedly reduced in siCD147-transduced cells when compared to the level in
siControl cells, as observed with immunoblotting (Figure S1). Then, we measured the effect of CD147
knockdown on HCMV-induced activation of the IFN-β and NF-κB promoters using a dual-luciferase
reporter assay in U251 cells. CD147 knockdown significantly reduced the activation of NF-κB and
IFN-β promoters that were stimulated by infection with HCMV, but not with Herpes simplex virus 1
(HSV-1) (Figure 1a). In addition, the ectopic expression of CD147-WT, but not the extracellular domain
(residues 1–185) or intracellular domain (residues 230–269) deletion mutants of CD147 (CD147-dECD
and CD147-dICD), restored promoter activity that was impaired by CD147-specific RNAi. These results
confirm the specific contribution of CD147 to the induction of NF-κB and IFN-β by HCMV infection
(Figure 1b). We next examined whether the endogenous CD147 was required for HCMV-induced
antiviral signaling under physiological conditions. We found that the knockdown of CD147 expression
in HFF cells decreased the activation of IFNB1 and interferon-stimulated ISG15 gene expression
induced by HCMV infection, as well as expression of the NF-κB downstream genes IL-6 and TNF-α
(Figure 1c). Together, these data suggest that CD147 might block the HCMV-triggered early antiviral
immune responses in a virus-specific manner.
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Figure 1. CD147 is involved in Human Cytomegalovirus (HCMV)-triggered early antiviral response. 
(a) Luciferase assay analyzing NF-κB and IFN-β promoter activity in non-targeting control siRNA 
(siControl) or CD147-specific short hairpin RNA (siCD147) stable U251 cells (2 × 105) transfected for 
36 h with a plasmid encoding an NF-κB or IFN-β firefly luciferase reporter (0.1 μg), along with a 
Renilla luciferase reporter control plasmid (pRL-TK, 0.01 μg), then left uninfected (UI) or infected for 
6 h with HCMV or HSV-1 (multiplicity of infection (MOI) = 0.5); (b) Luciferase assay analyzing 
NF-κB and IFN-β promoter activity in siControl or siCD147 stable U251 cells (2 × 105) transfected for 
36 h with a plasmid encoding an NF-κB or IFN-β firefly luciferase reporter (0.1 μg) and an expression 
plasmid for the wildtype CD147 (CD147-WT), or the mutants (CD147-dECD and CD147-dICD) (0.1 
μg), along with a Renilla luciferase reporter control plasmid (pRL-TK, 0.01 μg), then left uninfected 
(UI) or infected for 6 h with HCMV before the luciferase assays were performed (MOI = 0.5); and, (c) 
Quantitative real-time polymerase chain reaction (RT-PCR) analysis of IFNB1, ISG15, IL-6 and TNF 
mRNA in siControl or siCD147 stable human foreskin fibroblast (HFF) cells with HCMV uninfected 
(UI) or infected (MOI = 0.5) for 6 h. The graphical data are presented as the means ± the SDs (n = 3); 
NS denotes not significant (p > 0.05); * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001. 
3.2. CD147-Mediated HCMV-Triggered Antiviral Signaling via sCyPA-CD147 Interaction Activated 
ERK/NF-κB Pathway 
From the results above, one might assume that CD147 acts as a receptor for HCMV infection. 
However, CD147 had no significant effect on HCMV entry, either when tested with a 
function-blocking antibody against CD147 to inhibit HCMV infection of HFF cells, or when the 
expression of CD147 was knocked down in U251 cells (Figure S2). In our previous report that agreed 
well with the findings of other studies, we found that CyPA can bind directly to the ectodomain of 
CD147, and could therefore be responsible for the pro-inflammatory effect of CD147 [18]. Thus, we 
had reason to speculate that HCMV infection might promote the expression and release of cellular 
CyPA, which could then lead to the activation of innate immune signaling through the interaction 
with CD147. To test this hypothesis, we analyzed the kinetics of CypA RNA expression by 
quantitative real-time PCR, intracellular CypA (inCypA), and secreted CypA (sCypA) protein levels 
by Western blot analysis following HCMV infection of HFF cells. As shown in Figure 2a, the relative 
mRNA levels of CypA RNA expression were gradually up-regulated after HCMV infection. 
Additionally, both inCypA and sCypA were highly expressed at 12 post-infection (hpi), followed by 
a gradual increase in expression level with prolonged HCMV infection (Figure 2b). 
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Fro the results above, one ight assu e that CD147 acts as a receptor for HC V infection.
However, CD147 had no significant effect on HCMV entry, either when tested with a function-blocking
antibody against CD147 to inhibit HCMV infection of HFF cells, or when the expression of CD147 was
knocked down in U251 cells (Figure S2). In our previous report that agreed well with the findings of
other studies, we found that CyPA can bind directly to the ectodomain of CD147, and could therefore
be responsible for the pro-inflammatory effect of CD147 [18]. Thus, we had reason to speculate that
HCMV infection might promote the expression and release of cellular CyPA, which could then lead to
the activation of innate immune signaling through the interaction with CD147. To test this hypothesis,
e analyzed the kinetics of CypA RNA expression by quantitative real-time PCR, intracellular CypA
(inCypA), and secreted CypA (sCypA) protein levels by Western blot analysis following HCMV
infection of HFF cells. As shown in Figure 2a, the relative mRNA levels of CypA RNA expression were
gradually up-regulated after HCMV infection. Additionally, both inCypA and sCypA were highly
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expressed at 12 post-infection (hpi), followed by a gradual increase in expression level with prolonged
HCMV infection (Figure 2b).
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Figure 2. CD147 mediated HCMV-triggered antiviral signaling via the sCyPA-CD147 interaction 
activated ERK/NF-κB pathway. (a) Quantitative RT-PCR analysis of Cyclophilin A (CyPA) mRNA 
expression kinetics in HFF cells at different time points post-HCMV infection (MOI = 5); (b) Western 
blot analysis of secreted CypA (sCypA) protein levels and intracellular CypA (inCypA) in total 
protein lysates in culture mediums of HFF cells at the indicated times post HCMV infection (MOI = 
5); (c) Western blot analysis of the phosphorylation levels of ERK1/2 (p-ERK1/2), NF-κB p65 subunit 
(p-p65) and IRF3 (p-IRF3) in response to HCMV infection for 6 h (MOI = 0.5) compared to mock 
infection (Mock) with the medium only. The intensities of bands were quantified by Image Lab 4.0 
(Bio-Rad) and relative values normalized to GAPDH are indicated by the numbers under the lanes; 
(d) Analysis of the phosphorylation activation of ERK1/2, induced by HCMV infection for 6 h (MOI = 
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Figure 2. CD147 mediated HCMV-triggered antiviral signaling via the sCyPA-CD147 interaction
activated ERK/NF-κB pathway. (a) Quantitative RT-PCR analysis of Cyclophilin A (CyPA) mRNA
expression kinetics in HFF cells at different time points post-HCMV infection (MOI = 5); (b) Western
blot analysis of secreted CypA (sCypA) protein levels and intracellular CypA (inCypA) in total protein
lysates in culture mediums of HFF cells at the indicated times post HCMV infection (MOI = 5);
(c) Western blot analysis of the phosphorylation levels of ERK1/2 (p-ERK1/2), NF-κB p65 subunit
(p-p65) and IRF3 (p-IRF3) in response to HCMV infection for 6 h (MOI = 0.5) compared to mock
infection (Mock) with the medium only. The intensities of bands were quantified by Image Lab
4.0 (Bio-Rad) and relative values normalized to GAPDH are indicated by the numbers under the
lanes; (d) Analysis of the phosphorylation activation of ERK1/2, induced by HCMV infection for 6 h
(MOI = 0.5) with the culture medium, pre-supplemented with cyclosporine (CsA) (5 µg/mL) or CD147
mAb (50 µg/mL).
In previous studies, CyPA has been demonstrated to activate NF-κB by the ERK1/2 pathway
through the CyPA-CD147 interaction, which promotes an inflammatory effect in monocytes and
macrophages [28]. The transcription factors p65 and IRF3 play key roles in the induction of cellular
antiviral responses. Phosphorylation of p65 and IRF3 is required for their activity and constitutes a key
checkpoint. Thus, we next determined whether CD147-mediates HCMV-triggered antiviral signaling
by the activation of ERK in HFF cells. As shown in Figure 2c, the phosphorylation levels of ERK1/2
(p-ERK1/2), NF-κB p65 subunit (p-p65), and IRF3 (p-IRF3) were increased in response to HCMV
infection when compared to mock infection with the medium only. However, when endogenous CD147
expression was knocked down by lentiviral-based transduction of CD147-specific short hairpin RNA
(siCD147), HCMV-induced phosphorylation levels of ERK1/2 and p65 were dramatically reduced
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relative to the siControl group. The decreased activation of ERK1/2 and p65 phosphorylation were
more obvious than the level of IRF3, potentially emphasizing the importance and leading role of ERK
and NF-κB activation in signal transduction. Furthermore, CD147-blocking mAb and cyclosporine
(CsA), a novel inhibitor of CyPA that can specifically block the direct binding of CyPA to CD147,
also inhibited the HCMV-induced phosphorylation of ERK1/2 (Figure 2d). Together, these results
suggest that HCMV infection triggers the secretion of CyPA, which then activates the phosphorylation
of ERK and downstream NF-κB through interaction with CD147, which ultimately promotes cellular
antiviral signaling pathways.
3.3. HCMV miR-US25-1-5p Targeted and Down-Regulated CD147
Due to the potential role that CD147 may play in the HCMV early antiviral signaling mentioned
above, we next investigated the influence of HCMV infection on the expression kinetics of cellular
CD147 during different phases of the HCMV replication cycle. The protein expression levels of CD147
were dramatically down-regulated after 24 hpi of HCMV infection (Figure 3a), corresponding to a
decrease in the relative RNA expression (Figure 3b). It is well known that microRNAs encoded by
HCMV play essential roles in all aspects of the HCMV life cycle through the manipulation of many
cellular signaling pathways. Thus, we next investigated whether the expression of CD147 was targeted
and down-regulated by one of the HCMV-encoded 24 mature miRNAs previously identified in the
reactome database (www.reactome.org). Using RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/
rnahybrid/submission), we screened 14 HCMV-encoded mature miRNA candidates that might target
the 3′ UTR region of CD147. To experimentally determine which HCMV-encoded miRNAs targets
CD147, a pmirGLO dual luciferase reporter plasmid containing the 3′ UTR sequence of human CD147
downstream of the firefly luciferase gene was generated. Transfection of Human Embryonic Kidney
293 cells (293 cells) with each of the individual 14 putative HCMV miRNA constructs, and subsequent
luciferase assay, suggested that CD147 was most likely targeted by miR-US25-1-5p (Figure 3c). The most
likely target site for miR-UL25-1-5p was identified by RNAhybrid in the 3′ UTR region of CD147
mRNA (Figure 3d).
We next performed site-directed mutagenesis on the seed sequence of the predicted target site
in the pmirGLO-CD1473
′UTR reporter construct. As indicated by Luciferase assays, the mutation of
this site almost completely rescued the knockdown of CD147 by miR-UL25-1-5p in the wild type (WT)
construct (Figure 3e). We then tested whether transfection of the miR-UL25-1-5p mimic could target
endogenous CD147 in HCMV permissive U251 cells. When compared to cells that were transfected
with a non-targeting control siRNA (NC) or miR-UL25-1-3p mimic, the CD147 protein level was
appreciably reduced after the transfection of the miR-UL25-1-5p mimic. Notably, the efficiency was
almost comparable to the commercial siRNA against CD147 (miR-CD147) (Figure 3f). These results
indicate that miR-UL25-1-5p efficiently targets and down-regulates endogenous CD147 via a specific
location site in the 3′ UTR sequence.
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Figure 3. CD147 is targeted and down-regulated by HCMV miR-US25-1-5p. (a) Western blot
analysis of CD147 protein levels in total protein lysates of HFF cells at the indicated times
post HCMV infection (MOI = 5); (b) Quantitative RT-PCR analysis of CD147 mRNA expression
levels in HFF cells at the corresponding time points post-HCMV infection (MOI = 5); (c) Dual
luciferase reporter assay in 293 cells suggests that CD147 3′ UTR is targeted by miR-US25-1-5p.
A luciferase reporter plasmid pmirGLO-CD1473
′UTR was tested; the 14 putative HCMV mimics are
outlined in the abbreviations. Stars indicate potential down-regulated relative luciferase activities
and the corresponding p value; (d) Schematic of miR-US25-1-5p-binding sites on CD147 3′ UTR
(CD1473
′UTR) and its mutant CD1473
′UTRm, with the seed-recognizing site marked in red. The predicted
hybrid free-energy of miR-US25-1-5p is indicated; (e) Confirmation of the predicted target site for
miR-US25-1-5p. The 293T cells were co-transfected with miR-US25-1-5p mimic and the luciferase
reporter pmirGLO-CD1473
′UTR (WT) or pmirGLO-CD1473
′UTRm (MUT) for 36 h before dual luciferase
reporter assay; and, (f) Confirmation that miR-US25-1-5p (5p), but not miR-US25-1-3p (3p) specifically
down-regulates endogenous CD147 in U251 cells transfected as indicated and harvested two days
after transfection for Western Blot analysis. Commercial non-targeting control siRNAs (NC) and
CD147-specific siRNAs (siCD147) were used for comparisons. The graphical data are presented as the
means ± the SDs (n = 3); NS denotes not significant (p > 0.05); ** denotes p < 0.01.
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3.4. miR-US25-1-5p Inhibits CD147-Mediated Early Innate Immune Response to HCMV
We next determined if miR-US25-1-5p had the same effect as the CD147-specific short hairpin RNA
on the CD147-mediated early innate immune response to HCMV. miR-US25-1-5p stably transfected
HFF cells were constructed using the lentiviral-based transduction method. As shown in Figure S1b,
the expression of CD147 obviously decreased in miR-US25-1-5p transduced cells when compared
with the level in siControl cells that was observed by Western blot analysis. We then confirmed that
knockdown of the CD147 expression by miR-US25-1-5p could specifically reduce the activation of
IFNB1 and interferon-related gene ISG15 and the NF-κB downstream genes IL-6 and TNF-α induced
by HCMV early infection. These effects were similar to the effect of the CD147-specific siRNA studied
above (Figure 4). More importantly, activation of these innate immune related genes by HCMV
infection was also dramatically impaired in the siControl group when the culture medium was treated
with cyclosporin A (CsA), a CyPA specific inhibitor that has been proven to block the CypA-CD147
interaction [29]. miR-US25-1-5p and CsA appeared to have redundant roles in the inhibition of the
CD147-mediated early innate immune response to HCMV infection, since the addition of CsA to
the miR-US25-1-5p transduced cell group had no effect on the transcriptional up-regulation of these
genes. Taken together, these findings suggest that miR-US25-1-5p could function as a CD147-specific
short hairpin RNA to inhibit the CD147-mediated early innate immune response to HCMV infection,
and further supports the importance of the sCyPA-CD147 interaction in this process.
Viruses 2017, 9, 365 11 of 17 
 
3.4. miR-US25-1-5p Inhibits CD147-Mediated Early Innate Immune Response to HCMV 
We next determined if miR-US25-1-5p had the same effect as the CD147-specific short hairpin 
RNA on the CD147-mediated early innate immune response to HCMV. miR-US25-1-5p stably 
transfected HFF cells were constructed using the lentiviral-based transduction method. As shown in 
Figure S1b, the expression of CD147 obviously decreased in miR-US25-1-5p transduced cells when 
compared with the level in siControl cells that was observed by Western blot analysis. We then 
confirmed that knockdown of the CD147 expression by miR-US25-1-5p could specifically reduce the 
activation of IFNB1 and interferon-related gene ISG15 and the NF-κB downstream genes IL-6 and 
TNF-α induced by HCMV early infection. These effects were similar to the effect of the 
CD147-specific siRNA studied above (Figure 4). More importantly, activation of these innate 
immune related genes by HCMV infection was also dramatically impaired in the siControl group 
when the culture medium was treated with cyclosporin A (CsA), a CyPA specific inhibitor that has 
been proven to block the CypA-CD147 interaction [29]. miR-US25-1-5p and CsA appeared to have 
redundant roles in the inhibition of the CD147-mediated early innate immune response to HCMV 
infection, since the addition of CsA to the miR-US25-1-5p transduced cell group had no effect on the 
transcriptional up-regulation of these genes. Taken together, these findings suggest that 
miR-US25-1-5p could function as a CD147-specific short hairpin RNA to inhibit the CD147-mediated 
early innate immune response to HCMV infection, and further supports the importance of the 
sCyPA-CD147 interaction in this process. 
 
Figure 4. miR-US25-1-5p inhibits CD147-mediated early innate immune response to HCMV. 
Quantitative RT-PCR analysis of IFNB1, ISG15, IL-6, and TNF mRNA in siControl or miR-US25-1-5p 
stable HFF cells with HCMV uninfected (UI) or infected (MOI = 0.5) for 6 h and CsA present (HCMV 
+ CsA) or absent in the culture medium. The graphical data are presented as the means ± the SDs (n = 
3); NS denotes not significant (p > 0.05); * denotes p < 0.05, ** denotes p < 0.01. 
Figure 4. miR-US25-1-5p inhibits CD147-mediated early innate immune response to HCMV.
Quantitative RT-PCR analysis of IFNB1, ISG15, IL-6, and TNF mRNA in siControl or miR-US25-1-5p
stable HFF cells with HCMV uninfected (UI) or infected (MOI = 0.5) for 6 h and CsA present
(HCMV + CsA) or absent in the culture medium. The graphical data are presented as the means
± the SDs (n = 3); NS denotes not significant (p > 0.05); * denotes p < 0.05, ** denotes p < 0.01.
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3.5. Mutation of miR-US25-1-5p or Ectopic Expression of CD147 Delays HCMV Lytic Propagation at
Low MOI
To further evaluate the biological significance of HCMV miR-US25-1-5p targeting of CD147,
we generated a mutant HCMV (mUS25-1-5p) by HCMV BAC mutagenesis. To prevent any potential
artifacts resulting from full sequence deletion, the mutants were constructed, by substituting only
three nucleotides of the seed sequence of miR-US25-1-5p, corresponding to the putative CD147
mRNA 3′ UTR target site (Figure 5a). A revertant virus (RvWT) was constructed as a control.
In addition, we constructed a U251 cell line that stably overexpresses CD147, as well as control
U251 cell line. Effective loss of function in the interference of CD147 expression after infection with
HCMV-mUS25-1-5p (Figure S3a), rescued down-regulation of CD147 with the RvWT (Figure S3b),
and sustained overexpression of CD147 in pcDNA3.1-CD147 stably-transfected U251 cells for at least
14 days in comparison to control cells (Figure S1a), were confirmed by Western blot analysis.
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Figure 5. Mutation of miR-US25-1-5p or ectopic expression of CD147 can delay HCMV lytic
propagation at low MOI. (a) Schematic construction of HCMV mUS25-1-5p and the revertant wild
type (RvWT) with bacterial artificial chromosom (BAC) mutagenesis technique. U251 control cells
(U251-C) were infected with the HCMV wild-type virus, RvWT or HCMV-mUS25-1-5p mutant virus
(mUS25-1-5p) and CD147-overexpressing cells (U251-CD147) were infected with HCMV wild-type
virus at an MOI of (b) 0.05 or (c) 3. Cell-associated and supernatant virus were harvested at the dpi
indicated. Titers were determined by plaque assay. The values obtained were averages ± SD from
triplicate experiments. * Denotes p < 0.05, ** denotes p < 0.01.
Next, we examined the effect of HCMV-mUS25-1-5p and ectopic expression of CD147, relative to
HCMV-WT (wild type), on different phases of the HCMV replication cycle. Multistep growth and
single-step growth curves were analyzed in the constructed U251 cells that were infected with
HCMV-mUS25-1-5p, RvWT, or HCMV-WT, at a low MOI of 0.05 or at a high MOI of 3, respectively.
The supernatant and cell-associated virus were harvested together at the dpi indicated. HCMV titers
were determined by virus plaque assay in HFF cells. As seen in Figure 5b, at a low MOI of 0.05,
when multiple replication cycles of infection were measured, both HCMV-mUS25-1-5p in control
U251 cells, and HCMV-WT in CD147 overexpressing U251 cells, displayed a similar slight delay in
viral growth with statistical significance, but ultimately reached the same titer plateau as HCMV-WT
in empty vector stably-transfected U251 cells. HCMV wild-type and the revertant RvWT showed
similar growth kinetics, and reached the replication plateau at almost seven days post-infection (dpi)
in U251-C cells. However, at the higher MOI, no differences in virus yield were observed, either in cells
infected with the HCMV mutant virus miR-US25-1-5p, or in cells overexpressing CD147 (Figure 5c).
Similar results were observed when the mutant HCMV-mUS25-1-5p and wild type viruses were
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used to infect HFF cells. These results indicate that HCMV miR-US25-1-5p targeting of CD147 might
promote the course of HCMV Lytic propagation at low MOI.
4. Discussion
Numerous cell surface glycoproteins, such as β2 microglobulin, annexin II, CD13, platelet-derived
growth factor receptor-α (PDGFR-α), epithelial growth factor receptor (EGFR), and β1 integrins,
have been suggested to act as receptors facilitating HCMV entry [30]. However, none of the
suggested glycoproteins has been validated as a bona fide receptor that is necessary for HCMV
infection of all the susceptible cell types. The in vivo broad tissue tropism of HCMV infection and
differences in permissiveness for different cell types suggest that HCMV likely uses distinct cell surface
receptors depending on the target cells. Thus, identifying the specific HCMV cellular receptors is
important for understanding the pathogenesis of HCMV. CD147/EMMPRIN is a transmembrane
receptor glycoprotein that is belonging to the immunoglobulin superfamily and expressed at varying
levels in many tissue cells. Notably, several bacterial pathogens, such as Neisseria meningitidis and
Plasmodium falciparum, as well as many viruses, including HIV-1, HBV, SARS-CoV, and measles
virus (Mev), have been previously found to infect target cells via CD147, indicating that it might
constitute an evolutionarily conserved pathogen receptor for infection and spread within tissues and
organisms [31]. Unfortunately, neither the infection-blocking experiment using CD147-specfic antibody,
nor the viral infection test with CD147-knockdown cells, showed any difference in facilitating HCMV
entry (Figure S2). Since a low passage clinical HCMV strain NR-1 was used in these experiments,
we assumed that CD147 does not function as a broad-spectrum receptor for HCMV infection, at least
in typical in vitro permissive cell lines.
In addition to the pathogen recognition receptor function, most transmembrane receptor proteins
have been proposed to mediate signal transduction pathways immediately upon pathogenic particle
attachment and penetration. CD147 belongs to the Type I membrane proteins and as a candidate tumor
biomarker, its expression is up-regulated in breast cancer tissue, lung carcinoma tissue, and bladder
cancer tissue, along with a tumor’s malignance, invasiveness, and metastasis [32]. CD147 has been
extensively studied since the discovery of its function in tumor progression and metastasis. Here,
we have explored a previously unknown role for CD147 in the host innate immune defense against
HCMV invasion. Cells detect HCMV infection as early as four to eight hours post-infection (hpi),
responding by producing NF-κB-dependent cytokines and an early peak of antiviral IFN [5,33].
Our experiments indicate that endogenous CD147 is required for the maximum activation of NF-κB
and IFN-β-associated antiviral signaling that is triggered by HCMV infection, possibly having a
redundant effect with other cell surface receptor glycoproteins (Figure 1). Many tumor-related proteins,
such as Programmed death 1 (PD-1) and PTEN, are known to play key roles in regulating the innate
immunity against viral and bacterial infection [34,35]. However, the involvement of CD147 in early
antiviral immunity appears to be specific to HCMV infection, since it does not extend to other
viruses, like HSV-1. Since the signaling pathways of CD147 remain to be well defined, we next
demonstrated that the phosphorylation of ERK1/2 and then nuclear translocation of NF-κB might play
a leading role in CD147-mediated HCMV-triggered antiviral signal transduction, with a subsequent
activation of the IRF3 phosphorylation and the orchestrated NF-κB-dependent cytokines, IRF3 plus
NF-κB-dependent interferon responses (Figure 6). This finding can be supported by the fact that NF-κB
is a key transcriptional enhancesome-component of the IFN-β, according to previous research [36,37].
Research has increasingly suggested that the modulation of the host immune microenvironment
is not only important for tumor virus-induced inflammatory carcinogenesis, but it is also critical for
persistent and latent viral infection. For example, cmvIL-10, a viral mimic of human IL-10 acquired
from the cellular genome, binds with a high affinity to the human IL-10 receptor, and limits the innate
and adaptive immune responses even more efficiently than IL-10 itself [38]. In this study, we have
demonstrated that HCMV infection leads to the expression and secretion of a cellular chemokine,
CyPA. Studies show that CypA, as an extracellular ligand for its receptor CD147, can be secreted by
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various cell types, including vascular smooth muscle cells, macrophages, and fibroblasts, and triggers
a cascade of inflammatory responses [39]. We demonstrated that CD147-mediated HCMV-triggered
phosphorylation of ERK1/2, and the activation of NF-κB depends on the release of CyPA from HCMV
infected cells and its interaction with CD147 (Figure 2). Although HCMV is highly species-specific
with no animal model yet known to support its replication, we speculate that secreted extracellular
CypA, triggered by HCMV infection, acts through a paracrine mechanism, to stimulate uninfected cells
to defend against a second wave of infection by the progeny virus through the interaction with CD147.
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Figure 6. General model for HCMV miR-US25-1-5p in attenuating CD147/EMMPRIN-mediated
HCMV-triggered early antiviral response. Upon HCMV infection, intracellular CypA is released. As a
paracrine proinflammatory cytokine, CyPA interacts with CD147 of those uninfected cells and tissues,
and stimulates the phosphorylation of ERK1/2. The activation of NF-κB then occurs, followed by
a subsequent activation of the IRF3 phosphorylation and the orchestrated NF-κB-dependent,
IRF3 plus NF-κB-dependent immune responses. HCMV-encoded miR-US25-1-5p targeting CD147,
CD147-blocking mAb, and an inhibitor of CyPA (CsA) can specifically inhibit this process.
Moreover, we found that endogenous CD147 was targeted by HCMV-encoded miR-US25-1-5p at
the 3′ UTR, which could replace CD147-specific siRNA mimics in inhibiting the CD147-mediated early
innate immune response to HCMV infection (Figure 4). Mutation of the HCMV miR-US25-1-5p seed
sequence or ectopic expression of CD147 resulted in delayed multistep growth curves at low MOI,
suggesting that miR-US25-1-5p targeting of CD147 is biologically significant (Figure 5b). MicroRNAs
(miRNAs) are small noncoding RNA molecules that generally target 3′ untranslated regions (3′ UTR)
of the mRNAs. Since the discovery of HCMV-encoded miRNAs, at least 26 mature miRNA species
encoded by 14 pre-miRNAs have been identified and reported to regulate multiple aspects of viral and
cellular processes, including viral replication, immune evasion, formation of the virion, and eukaryotic
translation [40]. The pre-HCMV-miR-US25-1, from which the mature miR-US25-1-5p is derived,
is encoded by the HCMV US24 and US26 intergenic regions [41]. miR-US25-1-5p has been reported
to be transcribed upon infection and highly expressed at 24 hpi, followed by a gradually increased
expression, during the course of HCMV infection [42]. One might expect that the cells would respond
differently to infection with the mutant virus (HCMV-mUS25-1-5p), at late times of HCMV infection,
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when the expression levels of CD147 were obviously down-regulated by miR-US25-1-5p. However,
we found no difference in the expression of ISGs after infection with the mutant virus. Based on
previous studies and our overall findings, the reasons might be complex. At the late stage of infection,
HCMV often uses multi-faceted and redundant strategies to regulate immune responses. Thus,
the effect of natural miR-US25-1-5p may not be able to be detectable at late times of HCMV infection.
We speculate that secreted extracellular CypA, which is triggered by HCMV infection, acts primarily
to defend uninfected cells against progeny HCMV virus released from neighboring infected cells.
As a result, the observed lack of differences in virus yield at the higher MOI, irrespective of the
mutation of miR-US25-1-5p in the targeting of CD147 mRNA 3′ UTR or ectopic expression of CD147,
are understandable (Figure 5c).
In summary, we have provided the first evidence that CD147, a non-HCMV receptor glycoprotein,
is targeted by HCMV-encoded miR-US25-1-5p. This may be a tactic that is acquired by HCMV
to antagonize the early innate immune response to benefit HCMV chronic infection. Additionally,
HCMV-induced paracrine effects of the HCMV-induced expression of CypA could cause an immune
microenvironment called “smoldering inflammation”, which could potentially contribute to the
development of many HCMV inflammatory disorders.
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